Top 5 Takeaways Increased Incidence: A significant rise in nontoxigenic Corynebacterium diphtheriae cases in Washington, with numbers increasing tenfold from 2012–2017 to 2018–2023. High-Risk Populations: Most cases occurred among residents

Top 5 Takeaways Prevalence of Positive Childhood Experiences (PCEs): About 53.1% of adults reported experiencing six to seven PCEs, while 12.2% reported two or fewer, indicating a varied prevalence across

Top 5 Takeaways Prevalence of Smoking: In 2021, 12.1% of women reported smoking before pregnancy, 5.4% during pregnancy, and 7.2% postpartum. Smoking cessation during pregnancy was reported by 56.1% of

Top 5 Takeaways High Proportion of Injuries Among Minorities: Emergency department (ED) visits for pedestrian injuries were disproportionately higher among six racial and ethnic minority groups, with the visit proportions

Top 5 Takeaways Increase in Group A Streptococcus Bacteremia: The University of Vermont Medical Center noted a substantial rise in cases of group A streptococcal bloodstream infections during 2022–2023, primarily

Top 5 Takeaways New Vaccination Recommendation: As of February 28, 2024, the Advisory Committee on Immunization Practices (ACIP) recommends an additional dose of the updated (2023–2024 Formula) COVID-19 vaccine for

Top 5 Takeaways Link between SDOH, HRSNs, and Mammography: Women experiencing more adverse Social Determinants of Health (SDOH) and Health-Related Social Needs (HRSNs) reported lower mammography use, highlighting significant barriers

Top 5 Takeaways New Vaccine Approval: The FDA has approved the Pfizer Pentavalent Meningococcal Vaccine (MenACWY-TT/MenB-FHbp, branded as Penbraya) for individuals aged 10–25 years to protect against serogroups A, B,

Top 5 Takeaways High Infection and Hospitalization Rates: Throughout the study period, SARS-CoV-2 infection rates ranged from 61.4 to 133.8 per 10,000 nursing home residents, with a peak of 133.8

Top 5 Takeaways Initial Vaccine Effectiveness: The original monovalent mRNA COVID-19 vaccine was 52% effective in preventing COVID-19-related hospitalization in children and adolescents when the last dose was received within